Bauersachs Rupert M, Lindhoff-Last Edelgard, Klamroth Robert, Koster Andreas, Schindewolf Marc, Magnani Harry
Cardioangiology Center Bethanien, Vascular Center and Coagulation Center, Im Prüfling 23, 60389 Frankfurt, Germany.
Center for Vascular Research, Munich, Hochkalter Strasse 4a, 81547 Munich, Germany.
Pharmaceuticals (Basel). 2024 Nov 25;17(12):1584. doi: 10.3390/ph17121584.
(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis. This update summarises current information on its pharmacology and reviews danaparoid dose management in a broad spectrum of clinical situations, including off-label indications. (2) Methods: Evidence from published clinical studies, case reports, compassionate use of danaparoid, and spontaneously reported serious adverse events is summarised and analysed by an interdisciplinary expert group to develop a consensus on dosing regimens of danaparoid for complex clinical situations, including vulnerable patient populations. (3) Results: Dosing regimens are proposed, together with monitoring recommendations and target anti-factor Xa ranges. (4) Conclusion: In a comprehensive summary detailed interdisciplinary dosing recommendations are described to provide a basis for safe and effective use of danaparoid.
(1) 背景：达那肝素钠是一种类肝素抗血栓药物，已用于非肝素诱导的血小板减少症（HIT）患者预防深静脉血栓形成（DVT）以及治疗伴有或不伴有血栓形成的肝素诱导的血小板减少症40多年。本更新总结了其药理学的当前信息，并回顾了达那肝素在广泛临床情况下的剂量管理，包括超说明书用药适应症。(2) 方法：一个跨学科专家组总结并分析了已发表的临床研究、病例报告、达那肝素的同情用药以及自发报告的严重不良事件的证据，以就达那肝素在复杂临床情况下（包括脆弱患者群体）的给药方案达成共识。(3) 结果：提出了给药方案以及监测建议和目标抗Xa因子范围。(4) 结论：在一份全面总结中，描述了详细的跨学科给药建议，为安全有效地使用达那肝素提供依据。
